Multitarget Drug Discovery Projects in CNS Diseases: Quantitative Systems Pharmacology as a Possible Path Forward
Authors:
- 1 October 2014
- journal article
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 6 (16) , 1757-1769
Abstract
Clinical development in brain diseases has one of the lowest success rates in the pharmaceutical industry, and many promising rationally designed single-target R&D projects fail in expensive Phase ...Keywords
This publication has 76 references indexed in Scilit:
- Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysisInternational Journal of Neuropsychopharmacology, 2013
- A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophreniaBMC Psychiatry, 2013
- Polypharmacy in psychiatry: A reviewMens Sana Monographs, 2013
- Blinded Prospective Evaluation of Computer-Based Mechanistic Schizophrenia Disease Model for Predicting Drug ResponsePLOS ONE, 2012
- The effects of PRX-07034, a novel 5-HT6 antagonist, on cognitive flexibility and working memory in ratsPsychopharmacology, 2011
- The Presynaptic Component of the Serotonergic System is Required for Clozapine's EfficacyNeuropsychopharmacology, 2010
- Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancerCritical Reviews in Oncology/Hematology, 2010
- Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national studyBMC Psychiatry, 2009
- Subunit-Selective Modulation of GABA Type A Receptor Neurotransmission and Cognition in SchizophreniaAmerican Journal of Psychiatry, 2008
- A Placebo-Controlled Add-On Trial of the Ampakine, CX516, for Cognitive Deficits in SchizophreniaNeuropsychopharmacology, 2007